In Europe, it is well established that a second medical use patent can be obtained for any second or further therapeutic use of a known drug, providing the use is novel and inventive. However, a recent judgment in the Netherlands highlights that this is a developing area of law, and that there is uncertainty.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Michiel Rijsdijk, Arnold + Siedsma, medical use patent, patent, Novartis, Paget disease,
